(Q35110720)

6 August 2017

title

Weaning and discontinuation of epoprostenol in children with idiopathic pulmonary arterial hypertension receiving concomitant bosentan (English)

1 reference

idiopathic pulmonary arterial hypertension

6 August 2017

main subject

0 references

author name string

D Dunbar Ivy

1

1 reference

6 August 2017

Aimee Doran

2

1 reference

6 August 2017

Lori Claussen

3

1 reference

6 August 2017

Deborah Bingaman

4

1 reference

6 August 2017

Anji Yetman

5

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 April 2004

1 reference

American Journal of Cardiology

6 August 2017

published in

1 reference

6 August 2017

volume

93

1 reference

6 August 2017

issue

7

1 reference

6 August 2017

page(s)

943-946

1 reference

Vasodilator therapy for primary pulmonary hypertension in children

6 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3138203

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3138203

Successful withdrawal of long-term epoprostenol therapy for pulmonary arterial hypertension

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3138203

Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3138203

Survival in primary pulmonary hypertension: the impact of epoprostenol therapy.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3138203

Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3138203

Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3138203

Expression of endothelin-1 in the lungs of patients with pulmonary hypertension.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3138203

Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial

27 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/15050507

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/15050507

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Bosentan therapy for pulmonary arterial hypertension

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/15050507

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1016/J.AMJCARD.2003.12.031

1 reference

6 August 2017

1 reference

6 August 2017

1 reference